Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (39)	2/1/1999 1:05:00 PM
From: JMarcus	Respond to of 423

I'm trying to reach Paul Herron again so that I can get answers to all of your questions. Until the company's website gets up later this week, you can find all of the press releases at fkpi.com According to the June 18 press release, the six tumor types that are the target of the Phase 2 trial are ovarian, melanoma, pancreatic, non-small cell lung, renal cell carcinoma and colon cancer. More later. Nice price move today. JMarcus

To: BRAVEHEART who wrote (39)	2/1/1999 7:09:00 PM
From: JMarcus	Read Replies (2) \| Respond to of 423

I traded several voice messages with Paul Heron of SUNP today, but we never connected. I understand that his phone was ringing off the hook with questions about today's stock rise on volume more than 50% higher than the highest volume day all of last year. You asked (inter alia) about DENSPM's toxicity profile. At his Informed Investor Forum presentation, CEO Stefan Berg said that the side effects were nausea and vomiting, which were dose-related. He believes that they are readily controllable by managing dosage of the drug, and opined that those side effects could also be managed with other drugs. For a cancer drug, these are obviously very tolerable side effects. Starting out DENSPM's Phase 2 testing in six separate solid tumor cancer types reflects SUNP's strategy of taking advantage of off-label usage in multiple tumor types after first getting fast FDA approval in the tumor type where efficacy is most easily proven. DENSPM is being tested as a monotherapy for cancer, which will create the biggest marketing impact if the trials are successful. Stefan Berg had described the the DENSPM trial design as an "Ensign" protocol. I am not familiar with that term, which describes the three stage approach of simultaneously testing the drug in multiple indications and narrowing it down to the most promising indications in the second and third stages. Apparently the FDA has approved this approach for certain cancer monotherapy trials in the past. I still owe you answers on your other questions. I know that the University of Florida is a major stockholder, but I haven't learned yet who the other major investors are. Marc